A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression
Part of paid clinical trials in Phoenix, Arizona.
- Sponsor
- Draig Therapeutics Ltd
- Study ID
- NCT07610473
- Phase
- PHASE2
- Status
- Recruiting
Conditions
- Major Depressive Disorder (MDD)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- DT-101 — DRUGDT-101
- Placebo — DRUGPlacebo
Study Details
In this study, researchers will learn more about a study drug called DT-101 in participants with Major Depressive Disorder (MDD), a form of depression. The goal of this clinical trial is to learn if DT-101 can treat depression in adults. The effect of DT-101 will be compared to placebo. A placebo looks the drug but contains no medicine. Subjects will attend the clinic for complete general health checks and to complete questionnaires.
Key Dates
- First listed
- May 28, 2026
- Start date
- May 14, 2026
- Status verified
- May 2026
- Primary completion
- May 31, 2027
- Completion
- May 31, 2027
Study Design
- Enrollment
- 118 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: DT-101
- Placebo Comparator: Placebo
Primary Outcome Measure
Change from baseline in total Montgomery Åsberg depression rating scale (MADRS) score, at Day 56 [ Time Frame: from enrolment to day 56 ]
Central Contacts
- Aeron-1 Clinical Team+44(0)2920028450
Locations (22)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Draig Clinical Site | Phoenix | Arizona | 85013 | |
| Draig Clinical Site | Little Rock | Arkansas | 72211 | |
| Draig Clinical Site | Bellflower | California | 90706 | |
| Draig Clinical Site | Costa Mesa | California | 92626 | |
| Draig Clinical Site | Lafayette | California | 94549 | |
| Draig Clinical Site | Hialeah | Florida | 33016 | |
| Draig Clinical Site | Orlando | Florida | 32803 | |
| Draig Clinical Site | Orlando | Florida | 32807 | |
| Draig Clinical Site | Tampa | Florida | 33607 | |
| Draig Clinical Site | Tampa | Florida | 33613 | |
| Draig Clinical Site | Decatur | Georgia | 30030 | |
| Draig Clinical Site | Chicago | Illinois | 60610 | |
| Draig Clinical Site | Skokie | Illinois | 60076 | |
| Draig Clinical Site | Boston | Massachusetts | 02130 | |
| Draig Clinical Site | New York | New York | 10025 | |
| Draig Clinical Site | New York | New York | 10029 | |
| Draig Clinical Site | Columbus | Ohio | 43215 | |
| Draig Clinical Site | Allentown | Pennsylvania | 18103 | |
| Draig Clinical Site | Media | Pennsylvania | 19063 | |
| Draig Clinical Site | DeSoto | Texas | 75115 | |
| Draig Clinical Site | Fort Worth | Texas | 76104 | |
| Draig Clinical Site | Bellevue | Washington | 98007 |
Find similar trials in Phoenix, AZ
Related Studies
- Pilot Study: Establishing Glutamatergic Changes in Rapid Antidepressant Effects of KetamineEARLY_PHASE1 · Recruiting · University of Pennsylvania · Philadelphia, Pennsylvania
- A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive DisorderPHASE3 · Recruiting · Cybin IRL Limited · Birmingham, Alabama
- Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive DisorderPHASE3 · Recruiting · Vanda Pharmaceuticals · Phoenix, Arizona
- Orexin Antagonism for Suicide Risk: A Proof-of-Concept Clinical TrialPHASE2 · Recruiting · Marianne Goodman · The Bronx, New York